A
4.41
-0.25 (-5.37%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Astria Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.6
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 1.63 |
|
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.47% |
| 机构持股比例 | 104.65% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 28.00 (Wedbush, 535.64%) | 购买 |
| 中 | 26.00 (490.24%) | |
| 低 | 16.00 (HC Wainwright & Co., 263.22%) | 购买 |
| 平均值 | 24.00 (444.84%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 6.89 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wedbush | 12 Mar 2025 | 28.00 (535.64%) | 购买 | 7.14 |
| HC Wainwright & Co. | 11 Mar 2025 | 16.00 (263.22%) | 购买 | 6.47 |
| 27 Feb 2025 | 16.00 (263.22%) | 购买 | 6.31 | |
| Citizens Capital Markets | 03 Mar 2025 | 26.00 (490.24%) | 购买 | 6.10 |
| JMP Securities | 31 Jan 2025 | 26.00 (490.24%) | 购买 | 7.86 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合